US Senate pace slows on user fee bill
This article was originally published in Clinica
Sometimes the only train running is the slow one. The US Senate began debate April 30 on a bill designed primarily to reauthorise laws that request prescription drug and medical device companies to pay the Food and Drug Administration (FDA) user fees in exchange for speedier product reviews. However, since the bill is likely to represent the only chance that members of Congress will get to address a whole host of other regulatory issues governed by the Food, Drug and Cosmetic Act, many members want to make their mark on issues that are only tangentially related.